Guj. Themis Bio.

What is the bonus history of the Guj. Themis Bio.?

Gujarat Themis Biosyn Ltd announced a 1:2 bonus issue, with an ex-date of August 9, 2024, meaning shareholders will receive 1 additional share for every 2 shares held.

Gujarat Themis Biosyn Ltd has a recent bonus issue history where they announced a 1:2 bonus. The ex-date for this bonus is set for August 9, 2024. This means that for every 2 shares held, shareholders will receive 1 additional share. If you need further details or have more questions about the company, feel free to ask!

Has Guj. Themis Bio. declared dividend?

Gujarat Themis Biosyn Ltd has declared a 25% dividend, amounting to ₹0.25 per share, with an ex-date of July 15, 2024. The company has shown strong total returns over various periods, particularly impressive over the long term, despite recent fluctuations.

Gujarat Themis Biosyn Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 0.25<BR>- Ex-date: 15 Jul 24<BR><BR>Dividend Yield: 0.05%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -4.51%, the dividend return was 0%, resulting in a total return of -4.51%.<BR><BR>Over the past year, the price return was 24.43%, the dividend return was 0.09%, leading to a total return of 24.52%.<BR><BR>In the two-year period, the price return was 215.74%, the dividend return was 1.90%, culminating in a total return of 217.64%.<BR><BR>For the three-year period, the price return was 477.99%, the dividend return was 19.37%, resulting in a total return of 497.36%.<BR><BR>In the four-year span, the price return was 768.42%, the dividend return was 36.29%, which led to a total return of 804.71%.<BR><BR>Over the last five years, the price return was 1327.87%, the dividend return was 64.80%, resulting in a total return of 1392.67%.<BR><BR>Overall, Gujarat Themis Biosyn Ltd has declared a dividend while also showing significant total returns over various periods, particularly impressive over the longer term, indicating strong performance despite recent fluctuations.

Who are the peers of the Guj. Themis Bio.?

Guj. Themis Bio.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, Panacea Biotec, IOL Chemicals, Novartis India, and Zota Health Care. Guj. Themis Bio. has average growth and management risk, with a 1-year return of 22.35%, higher than Orchid Pharma but lower than Panacea Biotec's 269.46%.

Peers: The peers of Guj. Themis Bio. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Orchid Pharma, Panacea Biotec, IOL Chemicals, Novartis India, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, and Guj. Themis Bio., while Average management risk is found at IOL Chemicals and Novartis India, and Below Average management risk is noted at Orchid Pharma, Panacea Biotec, and Zota Health Care. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Guj. Themis Bio., Orchid Pharma, Panacea Biotec, and Zota Health Care, with Average growth at IOL Chemicals and Good growth at Novartis India. Excellent capital structure is held by Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Guj. Themis Bio., IOL Chemicals, and Novartis India, while Good capital structure is found at Torrent Pharma, and Below Average capital structure is noted at Orchid Pharma, Panacea Biotec, and Zota Health Care.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while the peer with the lowest is Orchid Pharma at -31.48%. Guj. Themis Bio.'s 1-year return of 22.35% is significantly higher than Orchid Pharma's but lower than Panacea Biotec's. Additionally, Orchid Pharma and Zota Health Care have negative six-month returns.

Is Guj. Themis Bio. overvalued or undervalued?

As of May 5, 2021, Guj. Themis Bio. is considered very expensive and overvalued with a PE Ratio of 72.45 and an EV to EBITDA of 51.24, significantly higher than competitors like Sun Pharma and Cipla, despite its impressive returns over the past three years.

As of 5 May 2021, the valuation grade for Guj. Themis Bio. moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently deemed overvalued. Key ratios include a PE Ratio of 72.45, an EV to EBITDA of 51.24, and a Price to Book Value of 15.82, all of which are substantially higher than industry peers. <BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE Ratio of 22.99 and an EV to EBITDA of 15.93, highlighting that Guj. Themis Bio. is trading at a premium relative to these competitors. Additionally, despite its high returns over various periods, including a 511.99% return over three years compared to the Sensex's 49.20%, the elevated valuation metrics suggest that the stock may not be justified at its current price level.

Who are in the management team of Guj. Themis Bio.?

As of March 2023, the management team of Guj. Themis Bio. includes Dinesh S Patel (Chairman), Sachin D Patel, and four independent non-executive directors: Vijay Gopi Kishan Agarwal, Kirandeep Madan, Vikram D Sanghvi, and Siddharth Y Kusumgar.

As of March 2023, the management team of Guj. Themis Bio. includes the following individuals:<BR><BR>1. Dinesh S Patel - Chairman & Non Executive Director<BR>2. Sachin D Patel - Non Executive Director<BR>3. Vijay Gopi Kishan Agarwal - Independent Non Executive Director<BR>4. Kirandeep Madan - Independent Non Executive Director<BR>5. Vikram D Sanghvi - Independent Non Executive Director<BR>6. Siddharth Y Kusumgar - Independent Non Executive Director<BR><BR>These members play various roles within the company's board of directors.

What does Guj. Themis Bio. do?

Gujarat Themis Biosyn Ltd is a small-cap pharmaceutical and biotechnology company, incorporated in 1981 and currently owned by the Yuhan Group. As of March 2025, it reported net sales of ₹377 Cr and a net profit of ₹120 Cr, with a market cap of ₹4,045 Cr.

Overview: <BR>Gujarat Themis Biosyn Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>The company was incorporated in 1981 and underwent a significant change in ownership in June 1991 when it was taken over by the Yuhan Group from South Korea and Pharmaceutical Business Group (India) Ltd. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 377 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 120 Cr (Quarterly Results - Mar 2025) <BR>Market cap: INR 4,045 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 83.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.05% <BR>Debt Equity: -0.03 <BR>Return on Equity: 21.83% <BR>Price to Book: 17.52 <BR><BR>Contact Details: <BR>Address: 69/C GIDC Industrial Estate, Valsad Dist VAPI Gujarat : 396195 <BR>Tel: 91-260-2430027 <BR>Email: accounts@gtbl.co.in/gtblmumbai@gtbl <BR>Website: http://www.gtbl.in

Who are the top shareholders of the Guj. Themis Bio.?

The top shareholders of Guj. Themis Bio include Pharmaceutical Business Group [India] Ltd with 47.02%, individual investors holding 19.31%, and foreign institutional investors at 2.51%. Additionally, mutual funds hold 1.16%, with Quant Mutual Fund - Quant Manufacturing Fund being the largest public shareholder at 1.15%.

The top shareholders of Guj. Themis Bio include the promoters, with the Pharmaceutical Business Group [India] Ltd holding the largest stake at 47.02%. Additionally, there are mutual funds involved, with five schemes collectively holding 1.16%, and foreign institutional investors (FIIs) holding 2.51% through ten different entities. The highest public shareholder is Quant Mutual Fund - Quant Manufacturing Fund, which has a holding of 1.15%. Individual investors also have a significant presence, owning 19.31% of the company.

How big is Guj. Themis Bio.?

As of 24th July, Gujarat Themis Biosyn Ltd has a market capitalization of 4,060.00 Cr, with Net Sales of 150.81 Cr and a Net Profit of 48.78 Cr for the latest four quarters. Shareholder's Funds are 201.38 Cr and Total Assets are 221.11 Cr as of March 2024.

As of 24th July, Gujarat Themis Biosyn Ltd has a market capitalization of 4,060.00 Cr, categorizing it as a Small Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 150.81 Cr and a Net Profit of 48.78 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 201.38 Cr and Total Assets of 221.11 Cr.

How has been the historical performance of Guj. Themis Bio.?

Guj. Themis Bio. experienced fluctuating net sales, reporting 150.80 Cr in Mar'25, down from 169.82 Cr in Mar'24 but up from 148.39 Cr in Mar'23. Profit metrics also declined, with profit after tax at 48.77 Cr in Mar'25, while total assets rose significantly to 301.31 Cr.

Answer:<BR>The historical performance of Guj. Themis Bio. shows a fluctuating trend in net sales and profitability over the years, with a notable increase in total operating income and profit margins in recent years.<BR><BR>Breakdown:<BR>Guj. Themis Bio. reported net sales of 150.80 Cr in Mar'25, a decrease from 169.82 Cr in Mar'24, but an increase from 148.39 Cr in Mar'23. The total operating income followed a similar pattern, peaking at 169.82 Cr in Mar'24 before declining to 150.80 Cr in Mar'25. The company's operating profit (PBDIT) was 71.27 Cr in Mar'25, down from 83.11 Cr in Mar'24, while profit before tax also decreased to 65.54 Cr from 79.33 Cr. Profit after tax for Mar'25 was reported at 48.77 Cr, a decline from 59.16 Cr in the previous year. The operating profit margin (excluding other income) was 45.65% in Mar'25, slightly down from 46.37% in Mar'24. Total assets increased significantly to 301.31 Cr in Mar'25 from 221.11 Cr in Mar'24, driven by a rise in total reserves to 237.49 Cr. The company also saw an increase in long-term borrowings to 29.64 Cr in Mar'25, compared to none in the previous year. Cash flow from operating activities improved to 91.00 Cr in Mar'25, up from 64.00 Cr in Mar'24, contributing to a net cash inflow of 5.00 Cr in Mar'25.

Is Guj. Themis Bio. technically bullish or bearish?

As of November 20, 2025, the trend is mildly bullish due to positive weekly MACD and KST signals, though caution is warranted from a mildly bearish weekly Dow Theory and lack of momentum in the RSI.

As of 20 November 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the weekly MACD and KST indicators showing bullish signals, while the daily moving averages also indicate a mildly bullish trend. However, the weekly Dow Theory is mildly bearish, which adds some caution. The RSI shows no signal on both weekly and monthly timeframes, suggesting a lack of momentum. Overall, the strength of the bullish stance is tempered by mixed signals from other indicators.

When is the next results date for Gujarat Themis Biosyn Ltd?

The next results date for Gujarat Themis Biosyn Ltd is February 5, 2026.

The next results date for Gujarat Themis Biosyn Ltd is scheduled for February 5, 2026.

Are Gujarat Themis Biosyn Ltd latest results good or bad?

Gujarat Themis Biosyn Ltd's latest Q3 FY26 results show strong sales growth at ₹43.37 crores, but a significant decline in net profit to ₹12.46 crores raises concerns about profitability and operational efficiency. Investors should be cautious as the company faces challenges in converting sales growth into profit.

Gujarat Themis Biosyn Ltd's latest results for Q3 FY26 present a mixed picture. On one hand, the company achieved its highest-ever quarterly sales of ₹43.37 crores, reflecting a growth of 2.41% quarter-on-quarter and 9.74% year-on-year. This indicates strong demand for its specialty pharmaceutical products.<BR><BR>However, the net profit has declined significantly, dropping to ₹12.46 crores, which is a decrease of 12.63% compared to the previous quarter and 3.93% year-on-year. This contraction in profit raises concerns about the company's operational efficiency and profitability margins, particularly as the PAT margin fell sharply to 28.73% from 33.67% in the previous quarter.<BR><BR>Overall, while the revenue growth is a positive sign, the decline in net profit and margins suggests that the company is facing challenges in translating its sales growth into bottom-line performance. Investors should be cautious and monitor how the company addresses these profitability issues moving forward.

Should I buy, sell or hold Gujarat Themis Biosyn Ltd?

Which are the latest news on Guj. Themis Bio.?

Why is Gujarat Themis Biosyn Ltd falling/rising?

As of 06-May, Gujarat Themis Biosyn Ltd's stock is experiencing a decline of 1.07% after two days of gains, underperforming its sector. Despite strong long-term returns, concerns over poor growth, high valuation, and decreased investor participation are driving the current downward trend.

As of 06-May, Gujarat Themis Biosyn Ltd's stock price is currently falling, with a change of -4.1, representing a decrease of 1.07%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 3.66% today, and it reached an intraday low of Rs 375, which is a drop of 2.01%. <BR><BR>Despite the stock's strong performance in the long term, with a 43.19% return over the past year and a remarkable 279.14% increase over the last three years, there are several concerning factors contributing to its current decline. The company has shown poor long-term growth, with net sales growing at an annual rate of only 11.22% and operating profit at 7.23% over the last five years. Additionally, the stock is trading at a premium compared to its peers, with a very expensive valuation indicated by a 12.8 enterprise value to capital employed ratio.<BR><BR>Investor participation has also decreased, as evidenced by a 6% drop in delivery volume compared to the five-day average. While the stock is trading above its moving averages, the overall market sentiment appears to be affected by the company's flat results and declining profits, which have fallen by 9.3% over the past year. These factors collectively contribute to the stock's current downward movement.